Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Xilio Therapeutics (XLO – Research Report), with a price target of $5.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Michael Ulz has given his Buy rating due to a combination of factors that highlight Xilio Therapeutics’ innovative approach and strategic collaborations. Xilio’s masked T-cell engager (TCE) platform, which includes advanced formats like ATACR and SEECR, shows promising results in preclinical studies. These formats are designed to enhance anti-tumor activity while minimizing the risk to healthy cells, offering a potentially superior therapeutic index compared to competitors.
Furthermore, the collaboration agreement with AbbVie not only validates Xilio’s tumor activation technology but also significantly extends the company’s financial stability. This partnership includes a substantial upfront payment and the potential for sizable contingent payments, providing a solid cash runway into the first quarter of 2026. These factors together suggest a strong potential for growth and success, justifying the Buy rating.
XLO’s price has also changed dramatically for the past six months – from $0.834 to $1.480, which is a 77.46% increase.